Folger Nolan Fleming Douglas Capital Management Inc. Trims Stake in Thermo Fisher Scientific Inc. $TMO

Folger Nolan Fleming Douglas Capital Management Inc. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 882 shares of the medical research company’s stock after selling 31 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Conning Inc. increased its stake in shares of Thermo Fisher Scientific by 27.7% in the 2nd quarter. Conning Inc. now owns 13,132 shares of the medical research company’s stock worth $5,325,000 after purchasing an additional 2,847 shares in the last quarter. Davis Rea LTD. increased its stake in Thermo Fisher Scientific by 14.8% in the 2nd quarter. Davis Rea LTD. now owns 43,294 shares of the medical research company’s stock worth $17,573,000 after buying an additional 5,582 shares in the last quarter. Blue Zone Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 7.5% in the 2nd quarter. Blue Zone Wealth Advisors LLC now owns 12,248 shares of the medical research company’s stock worth $4,966,000 after buying an additional 858 shares in the last quarter. JB Capital LLC increased its stake in Thermo Fisher Scientific by 64.7% in the 2nd quarter. JB Capital LLC now owns 11,903 shares of the medical research company’s stock worth $4,826,000 after buying an additional 4,676 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 3.0% in the 2nd quarter. Cyndeo Wealth Partners LLC now owns 4,866 shares of the medical research company’s stock worth $1,973,000 after buying an additional 140 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $524.95 on Friday. The firm has a market capitalization of $198.23 billion, a price-to-earnings ratio of 30.36, a PEG ratio of 2.90 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The business has a 50 day simple moving average of $488.68 and a 200-day simple moving average of $448.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays increased their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $593.43.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last 90 days. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.